Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-956-7 | CAS number: 2582-30-1
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline study and GLP
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
Test material
- Reference substance name:
- Aminoguanidinium hydrogen carbonate
- EC Number:
- 219-956-7
- EC Name:
- Aminoguanidinium hydrogen carbonate
- Cas Number:
- 2582-30-1
- Molecular formula:
- CH6N4.CH2O3
- IUPAC Name:
- carbamimidoyldiazanium hydrogen carbonate
- Test material form:
- other: solid
- Details on test material:
- content: 98.7 %
Constituent 1
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- other: HsdWin:DH
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source:
- Age at study initiation: 5-7 weeks
- Weight at study initiation: 316-406 g
- Housing: 2-3 per cage throughout the study
- Diet ad libitum
- Water ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21
- Humidity (%): 40-70
- Air changes (per hr): 12-15
- Photoperiod (hrs dark / hrs light): 12 / 12
Study design: in vivo (non-LLNA)
Induction
- Route:
- intradermal and epicutaneous
- Vehicle:
- physiological saline
Challenge
- Route:
- epicutaneous, semiocclusive
- Vehicle:
- physiological saline
- No. of animals per dose:
- 20
- Details on study design:
- intradermal induction : 5 %
topical induction 50 %
4 weeks after intradermal induction
first topical challenge 50 and 25 %
second challenge 50 and 25 % - Challenge controls:
- The animal of the control groups were treated in the same manner as the animals of the test substance group; however, the formulations did not contain any test substance but a corresponding amount of sterile physiological saline.
- Positive control substance(s):
- not specified
Results and discussion
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 50 %
- No. with + reactions:
- 4
- Total no. in group:
- 20
- Clinical observations:
- mild
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 50 %. No with. + reactions: 4.0. Total no. in groups: 20.0. Clinical observations: mild.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 50%
- No. with + reactions:
- 3
- Total no. in group:
- 20
- Clinical observations:
- mild
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 50%. No with. + reactions: 3.0. Total no. in groups: 20.0. Clinical observations: mild.
- Reading:
- other: rechallege 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 50 %
- No. with + reactions:
- 14
- Total no. in group:
- 20
- Clinical observations:
- readily visible
- Remarks on result:
- other: Reading: other: rechallege 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 50 %. No with. + reactions: 14.0. Total no. in groups: 20.0. Clinical observations: readily visible.
- Reading:
- other: rechallenge 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 50%
- No. with + reactions:
- 9
- Total no. in group:
- 20
- Clinical observations:
- readily visible
- Remarks on result:
- other: Reading: other: rechallenge 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 50%. No with. + reactions: 9.0. Total no. in groups: 20.0. Clinical observations: readily visible.
- Reading:
- 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25 %
- No. with + reactions:
- 8
- Total no. in group:
- 20
- Clinical observations:
- readily visible
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25 %. No with. + reactions: 8.0. Total no. in groups: 20.0. Clinical observations: readily visible.
- Reading:
- 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 7
- Total no. in group:
- 20
- Clinical observations:
- mild
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 25%. No with. + reactions: 7.0. Total no. in groups: 20.0. Clinical observations: mild.
- Reading:
- other: rechallenge 1st reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 25 %
- No. with + reactions:
- 9
- Total no. in group:
- 20
- Clinical observations:
- readily visible
- Remarks on result:
- other: Reading: other: rechallenge 1st reading. . Hours after challenge: 48.0. Group: test group. Dose level: 25 %. No with. + reactions: 9.0. Total no. in groups: 20.0. Clinical observations: readily visible.
- Reading:
- other: rechallenge 2nd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 25%
- No. with + reactions:
- 9
- Total no. in group:
- 20
- Clinical observations:
- readily visible
- Remarks on result:
- other: Reading: other: rechallenge 2nd reading. . Hours after challenge: 72.0. Group: test group. Dose level: 25%. No with. + reactions: 9.0. Total no. in groups: 20.0. Clinical observations: readily visible.
- Reading:
- other: controls
- Group:
- negative control
- Dose level:
- physiological saline
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- other: Reading: other: controls. Group: negative control. Dose level: physiological saline. No with. + reactions: 0.0. Total no. in groups: 10.0.
Applicant's summary and conclusion
- Interpretation of results:
- sensitising
- Remarks:
- Migrated information
- Executive summary:
The maximization test of Magnusson and Kligman was performed on male guinea pigs to determine whether aminoguanidinium hydrogen carbonate exhibits skin sensitization properties.
This GLP study was performed according to OECD Guideline No. 406.
The study was conducted with the following test concentrations.
intradermal induction: 5%
topical induction: 50 %
first challenge: 50 and 25 %
second challenge: 50 and 25 %
Aminoguanidinium hydrogen carbonate was formulated in sterile physiological saline solution to yield a suspension.
After the first challenge the 50 % and 25% aminoguanidinium hydrogen carbonate formulations led to skin redness in 20 % and 40 % of the test animals respectively There were no skin reactions in the control group.
After the second challenge the 50 % and 25 % aminoguanidinium hydrogen carbonate formulations led to skin redness in 70 % and 45 % of the test animals, respectively. There were no skin reactions in the control group.
Aminoguanidinium hydrogen carbonate thus exhibits a definitive skin-sensitization potential under the conditions of the maximization test.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
